Bridge City Capital LLC Purchases New Shares in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Bridge City Capital LLC acquired a new position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) during the second quarter, Holdings Channel.com reports. The firm acquired 22,814 shares of the company’s stock, valued at approximately $1,311,000.

A number of other institutional investors have also recently added to or reduced their stakes in the company. West Tower Group LLC purchased a new stake in shares of Amphastar Pharmaceuticals during the second quarter worth about $39,000. Point72 Middle East FZE purchased a new stake in Amphastar Pharmaceuticals during the 4th quarter worth approximately $50,000. Pacer Advisors Inc. acquired a new position in shares of Amphastar Pharmaceuticals in the 2nd quarter valued at approximately $59,000. Point72 Hong Kong Ltd purchased a new position in shares of Amphastar Pharmaceuticals during the 1st quarter valued at approximately $74,000. Finally, Tower Research Capital LLC TRC boosted its stake in shares of Amphastar Pharmaceuticals by 206.9% during the 1st quarter. Tower Research Capital LLC TRC now owns 1,998 shares of the company’s stock valued at $75,000 after buying an additional 1,347 shares during the last quarter. Institutional investors and hedge funds own 65.09% of the company’s stock.

Insider Buying and Selling

In other Amphastar Pharmaceuticals news, EVP Yakob Liawatidewi sold 28,816 shares of the firm’s stock in a transaction dated Monday, August 28th. The shares were sold at an average price of $53.13, for a total value of $1,530,994.08. Following the completion of the transaction, the executive vice president now directly owns 69,669 shares in the company, valued at $3,701,513.97. The sale was disclosed in a filing with the SEC, which is accessible through this link. In other news, Director Richard K. Prins sold 5,000 shares of the stock in a transaction that occurred on Monday, November 13th. The shares were sold at an average price of $52.50, for a total value of $262,500.00. Following the completion of the sale, the director now directly owns 35,895 shares of the company’s stock, valued at $1,884,487.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Yakob Liawatidewi sold 28,816 shares of the company’s stock in a transaction that occurred on Monday, August 28th. The shares were sold at an average price of $53.13, for a total transaction of $1,530,994.08. Following the completion of the transaction, the executive vice president now owns 69,669 shares in the company, valued at approximately $3,701,513.97. The disclosure for this sale can be found here. In the last quarter, insiders have sold 95,559 shares of company stock valued at $4,982,484. 28.40% of the stock is owned by corporate insiders.

Amphastar Pharmaceuticals Stock Performance

NASDAQ AMPH traded down $0.32 during trading hours on Friday, reaching $55.85. The company’s stock had a trading volume of 444,581 shares, compared to its average volume of 393,670. Amphastar Pharmaceuticals, Inc. has a 52 week low of $27.58 and a 52 week high of $67.66. The stock has a market cap of $2.73 billion, a PE ratio of 21.82 and a beta of 0.87. The company has a current ratio of 2.11, a quick ratio of 1.68 and a debt-to-equity ratio of 1.07. The business has a 50-day simple moving average of $47.41 and a 200 day simple moving average of $50.56.

Analyst Ratings Changes

A number of brokerages recently issued reports on AMPH. StockNews.com upgraded shares of Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Monday, November 13th. Jefferies Financial Group began coverage on Amphastar Pharmaceuticals in a research note on Tuesday, July 25th. They issued a “buy” rating and a $70.00 price target for the company. Piper Sandler lifted their target price on Amphastar Pharmaceuticals from $66.00 to $71.00 in a research report on Wednesday, August 9th. Finally, Bank of America assumed coverage on Amphastar Pharmaceuticals in a research report on Friday. They set a “neutral” rating and a $63.00 price target on the stock.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredient (API).